Population-based lung cancer screening with multislice CT substantially reduces mortality from the disease among high-risk former and current smokers, with larger risk reductions in women vs men, the NELSON study has shown.
Female patients with non-small-cell lung cancer (NSCLC) have markedly better survival than male NSCLC patients, according to the SWOG S0424 study presented at the International Association for the Study of Lung Cancer’s 19th World Conference on Lung Cancer (WCLC 2018).
The use of durvalumab after concurrent chemoradiation (cCRT) therapy reduces the risk of all-cause mortality by 32 percent in patients with unresectable stage III non-small-cell lung cancer (NSCLC), the PACIFIC trial has shown.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.